Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07221500 · ClinicalTrials.gov registry record · Phase 2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
A Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), sponsored by Nurix Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 18
- Study locations
NCT07221500 is a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) that is actively recruiting participants, run by Nurix Therapeutics. The registered enrollment target is 100 participants, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower). The trial reports 18 study locations across 10 states.
The verdict
NCT07221500, a Phase 2 study of Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL), is actively recruiting participants, sponsored by Nurix Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 18
- Study locations
Study Summary
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Conditions Studied
Interventions
- DRUG NX-5948
Study Locations (18)
Other
- CHU de Nantes - Nantes
- AUSL della Romagna UO Ematologia - Ravenna
- Pratia Hematologia Sp. z o.o. - Katowice
- Pratia S.A. - Krakow
- Aidport Sp. z o.o. - Skorzewo
- Pratia Warszawa / Pratia MTZ - Warsaw
- The Royal Marsden NHS Foundation Trust - London
- The Christie NHS Foundation Trust - Manchester
Ohio
- University of Cincinnati - Cincinnati
- Oncology Hematology Care - Fairfield
Colorado
- Colorado Blood Institute - Denver
Florida
- Florida Cancer Specialists - Sarasota
Maryland
- Maryland Oncology Hematology - Silver Spring
North Carolina
- Novant Health Cancer Institute - Winston-Salem
Tennessee
- SCRI Oncology Partners - Nashville
Texas
- Texas Oncology - Center South - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2030-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07221500
The ClinicalTrials.gov registry entry for NCT07221500 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (47% lower). The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 1 intervention - of which NX-5948 is the first listed.
NCT07221500 reports 18 study locations spanning 10 distinct geographic areas - top geographies include Other, Ohio, Colorado.
Frequently Asked Questions
What is clinical trial NCT07221500 about?
NCT07221500 is a clinical study titled "A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)". This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexo...
What is the current status of trial NCT07221500?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-15. Estimated completion is 2030-10.
What conditions does trial NCT07221500 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL).
What interventions are being tested in trial NCT07221500?
The interventions under investigation include: NX-5948 (DRUG).
Who is sponsoring clinical trial NCT07221500?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07221500 being conducted?
This trial has 18 study locations across Colorado, Florida, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
RECRUITING · Phase 2
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 2
-
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL)
ACTIVE NOT RECRUITING · Phase 2
-
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax
ACTIVE NOT RECRUITING · Phase 2
-
Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Chronic Lymphocytic Leukemia (CLL)
All registered trials for this condition
Small Lymphocytic Lymphoma (SLL)
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.